The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment.
HTA
Health Technology Assessment
elderly
influenza
quadrivalent adjuvanted influenza vaccine
vaccination
vaccines
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
31 03 2022
31 03 2022
Historique:
received:
20
02
2022
revised:
25
03
2022
accepted:
29
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
The elderly, commonly defined as subjects aged ≥65 years, are among the at-risk subjects recommended for annual influenza vaccination in European countries. Currently, two new vaccines are available for this population: the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose quadrivalent influenza vaccine (hdQIV). Their multidimensional assessment might maximize the results in terms of achievable health benefits. Therefore, we carried out a Health Technology Assessment (HTA) of the aQIV by adopting a multidisciplinary policy-oriented approach to evaluate clinical, economic, organizational, and ethical implications for the Italian elderly. A HTA was conducted in 2020 to analyze influenza burden; characteristics, efficacy, and safety of aQIV and other available vaccines for the elderly; cost-effectiveness of aQIV; and related organizational and ethical implications. Comprehensive literature reviews/analyses were performed, and a transmission model was developed in order to address the above issues. In Italy, the influenza burden on the elderly is high and from 77.7% to 96.1% of influenza-related deaths occur in the elderly. All available vaccines are effective and safe; however, aQIV, such as the adjuvanted trivalent influenza vaccine (aTIV), has proved more immunogenic and effective in the elderly. From the third payer's perspective, but also from the societal one, the use of aQIV in comparison with egg-based standard QIV (eQIV) in the elderly population is cost-effective. The appropriateness of the use of available vaccines as well as citizens' knowledge and attitudes remain a challenge for a successful vaccination campaign. The results of this project provide decision-makers with important evidence on the aQIV and support with scientific evidence on the appropriate use of vaccines in the elderly.
Sections du résumé
BACKGROUND
The elderly, commonly defined as subjects aged ≥65 years, are among the at-risk subjects recommended for annual influenza vaccination in European countries. Currently, two new vaccines are available for this population: the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose quadrivalent influenza vaccine (hdQIV). Their multidimensional assessment might maximize the results in terms of achievable health benefits. Therefore, we carried out a Health Technology Assessment (HTA) of the aQIV by adopting a multidisciplinary policy-oriented approach to evaluate clinical, economic, organizational, and ethical implications for the Italian elderly.
METHODS
A HTA was conducted in 2020 to analyze influenza burden; characteristics, efficacy, and safety of aQIV and other available vaccines for the elderly; cost-effectiveness of aQIV; and related organizational and ethical implications. Comprehensive literature reviews/analyses were performed, and a transmission model was developed in order to address the above issues.
RESULTS
In Italy, the influenza burden on the elderly is high and from 77.7% to 96.1% of influenza-related deaths occur in the elderly. All available vaccines are effective and safe; however, aQIV, such as the adjuvanted trivalent influenza vaccine (aTIV), has proved more immunogenic and effective in the elderly. From the third payer's perspective, but also from the societal one, the use of aQIV in comparison with egg-based standard QIV (eQIV) in the elderly population is cost-effective. The appropriateness of the use of available vaccines as well as citizens' knowledge and attitudes remain a challenge for a successful vaccination campaign.
CONCLUSIONS
The results of this project provide decision-makers with important evidence on the aQIV and support with scientific evidence on the appropriate use of vaccines in the elderly.
Identifiants
pubmed: 35409848
pii: ijerph19074166
doi: 10.3390/ijerph19074166
pmc: PMC8998177
pii:
doi:
Substances chimiques
Adjuvants, Immunologic
0
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
PLoS One. 2017 Jan 11;12(1):e0169801
pubmed: 28076411
Hum Vaccin Immunother. 2020 Nov 1;16(11):2680-2689
pubmed: 32347787
Health Aff (Millwood). 2002 May-Jun;21(3):166-8
pubmed: 12025980
Open Forum Infect Dis. 2019 Oct 29;6(11):ofz462
pubmed: 32258201
Vaccine. 2020 Jan 10;38(2):372-379
pubmed: 31606249
Eur J Health Econ. 2013 Jun;14(3):367-72
pubmed: 23526140
Vaccine. 2006 Oct 30;24(42-43):6468-75
pubmed: 16876293
BMC Public Health. 2022 Jan 6;22(1):19
pubmed: 34991544
Vaccine. 2016 Jul 29;34(35):4092-4102
pubmed: 27381642
J Infect Dis. 2020 Jun 29;222(2):278-287
pubmed: 32100009
Hum Vaccin Immunother. 2018 Mar 4;14(3):699-705
pubmed: 29059004
Expert Rev Vaccines. 2019 Nov;18(11):1201-1209
pubmed: 31674847
J Infect Dis. 2019 Sep 13;220(8):1255-1264
pubmed: 30561688
Lancet Infect Dis. 2021 Jul;21(7):1027-1037
pubmed: 33577767
Vaccine. 2020 Sep 22;38(41):6455-6463
pubmed: 32778474
Drugs Aging. 2019 Jan;36(1):29-37
pubmed: 30411283
Aging Clin Exp Res. 2021 Mar;33(3):711-717
pubmed: 31347085
Eur J Public Health. 2019 Oct 1;29(5):900-905
pubmed: 30929026
J Infect. 2011 May;62(5):379-87
pubmed: 21414357
Int J Technol Assess Health Care. 2020 Jun;36(3):187-190
pubmed: 32398176
Fam Pract. 2001 Dec;18(6):629-34
pubmed: 11739352
MMWR Recomm Rep. 2021 Aug 27;70(5):1-28
pubmed: 34448800
Vaccine. 2020 Jul 22;38(34):5398-5401
pubmed: 32600911
Vaccines (Basel). 2020 Jul 30;8(3):
pubmed: 32751584
PLoS One. 2021 Apr 8;16(4):e0248943
pubmed: 33831021
Vaccine. 2020 Jan 10;38(2):242-250
pubmed: 31635976
Vaccine. 2010 Apr 30;28(20):3558-62
pubmed: 20307592
Vaccine. 2021 Sep 15;39(39):5706-5718
pubmed: 34404557
Vaccines (Basel). 2020 Aug 07;8(3):
pubmed: 32784684
Int J Infect Dis. 2019 Nov;88:127-134
pubmed: 31401203
Clin Infect Dis. 2021 Dec 6;73(11):e4251-e4259
pubmed: 33211809
Influenza Other Respir Viruses. 2021 Nov;15(6):813-823
pubmed: 34081398
PLoS One. 2018 Sep 7;13(9):e0202787
pubmed: 30192781
Hum Vaccin Immunother. 2021 Nov 2;17(11):4603-4610
pubmed: 34550848
Expert Rev Pharmacoecon Outcomes Res. 2006 Jun;6(3):293-301
pubmed: 20528523
Am J Prev Med. 2016 Dec;51(6):1079-1083
pubmed: 27236479
Expert Rev Vaccines. 2022 Mar;21(3):289-296
pubmed: 34931919
PLoS One. 2013 Oct 07;8(10):e74785
pubmed: 24116010
J Prev Med Hyg. 2011 Mar;52(1):1-8
pubmed: 21710816
Influenza Other Respir Viruses. 2022 Mar;16(2):351-365
pubmed: 34704361
Front Public Health. 2021 Jun 24;9:658979
pubmed: 34249833
Med Health Care Philos. 2009 Nov;12(4):453-7
pubmed: 19507050
Front Public Health. 2022 Mar 09;10:786662
pubmed: 35359753